-
-
-
-
-
-
-
After-Hours Movers 11/18: (APVO) (CORT) (SONO) Higher; (WRN) (MGTX) (GPRO) Lower (more...)
-
-
-
-
-
-
-
MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at EURETINA 2020 Virtual Meeting
-
-
-
-
-
-
-
MeiraGTx Holdings plc (MGTX) Reports Positive Clinical Data from Ongoing Phase 1/2 Clinical Trial (NCT03252847) of AAV-RPGR
-
-
-
-
-
-
-
MeiraGTx (MGTX) Announces PPRIME) and ATMP Designations Granted by EMA to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
-
-
-
-
-
-
-
MeiraGTx Holdings plc (MGTX) to Present Clinical Data from Phase 1/2 Trial of AAV-RPE65 at Upcoming Scientific Conferences
-
-
-
-
-
-
-
MeiraGTx Announces Proposed Public Offering of Ordinary Shares
-
-
-
-
-
-
-
MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiency
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

